PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 1993 July; 37(7): 1539–1542.
PMCID: PMC188009

Suramin prevents duck hepatitis B virus infection in vivo.

Abstract

The effect of suramin on duck hepatitis B virus (DHBV) infection was investigated in vivo. Suramin pretreatment of Pekin ducklings completely prevented DHBV infection. In contrast, suramin given at the time of or after inoculation with DHBV did not inhibit viral infection, replication, or gene expression. These data indicate that suramin effectively blocks the early stages of DHBV infection in vivo.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, Klecker RW, Redfield RR, Mitsuya H, Hoth DF, Gelmann E, et al. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet. 1985 Sep 21;2(8456):627–630. [PubMed]
  • Collins JM, Klecker RW, Jr, Yarchoan R, Lane HC, Fauci AS, Redfield RR, Broder S, Myers CE. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 1986 Jan;26(1):22–26. [PubMed]
  • De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979 Nov;8(1):9–22. [PubMed]
  • de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 15;23(18):2495–2531. [PubMed]
  • Eisen V, Loveday C. Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation. Br J Pharmacol. 1973 Dec;49(4):678–687. [PMC free article] [PubMed]
  • Hensey CE, Boscoboinik D, Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett. 1989 Nov 20;258(1):156–158. [PubMed]
  • Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 1985;29(3):265–273. [PubMed]
  • Lambeir AM, Loiseau AM, Kuntz DA, Vellieux FM, Michels PA, Opperdoes FR. The cytosolic and glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei. Kinetic properties and comparison with homologous enzymes. Eur J Biochem. 1991 Jun 1;198(2):429–435. [PubMed]
  • LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Myers CE. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am. 1991 Feb;18(1):123–129. [PubMed]
  • Leff P, Wood BE, O'Connor SE. Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery. Br J Pharmacol. 1990 Nov;101(3):645–649. [PMC free article] [PubMed]
  • LOMINSKI I, GRAY S. Inhibition of lysozyme by 'Suramin'. Nature. 1961 Nov 18;192:683–683. [PubMed]
  • Mason WS, Seal G, Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol. 1980 Dec;36(3):829–836. [PMC free article] [PubMed]
  • Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science. 1984 Oct 12;226(4671):172–174. [PubMed]
  • Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Sulfated polyanions do not inhibit duck hepatitis B virus infection. Antimicrob Agents Chemother. 1991 Nov;35(11):2431–2433. [PMC free article] [PubMed]
  • Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Virology. 1991 Jul;183(1):415–418. [PubMed]
  • Offensperger WB, Walter E, Offensperger S, Zeschnigk C, Blum HE, Gerok W. Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. Virology. 1988 May;164(1):48–54. [PubMed]
  • Petcu DJ, Aldrich CE, Coates L, Taylor JM, Mason WS. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology. 1988 Dec;167(2):385–392. [PubMed]
  • Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989 Apr;7(4):499–508. [PubMed]
  • Tsiquaye KN, Collins P, Zuckerman AJ. Antiviral activity of the polybasic anion, suramin and acyclovir in Hepadna virus infection. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):223–228. [PubMed]
  • Tsiquaye K, Zuckerman A. Suramin inhibits duck hepatitis B virus DNA polymerase activity. J Hepatol. 1985;1(6):663–669. [PubMed]
  • Tuttleman JS, Pugh JC, Summers JW. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol. 1986 Apr;58(1):17–25. [PMC free article] [PubMed]
  • Walter E, Blum HE, Meier P, Huonker M, Schmid M, Maier KP, Offensperger WB, Offensperger S, Gerok W. Hepatocellular carcinoma in alcoholic liver disease: no evidence for a pathogenetic role of hepatitis B virus infection. Hepatology. 1988 Jul-Aug;8(4):745–748. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)